These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9525894)

  • 1. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3.
    Hammache D; Piéroni G; Yahi N; Delézay O; Koch N; Lafont H; Tamalet C; Fantini J
    J Biol Chem; 1998 Apr; 273(14):7967-71. PubMed ID: 9525894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
    Yahi N; Sabatier JM; Nickel P; Mabrouk K; Gonzalez-Scarano F; Fantini J
    J Biol Chem; 1994 Sep; 269(39):24349-53. PubMed ID: 7929093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O; Hammache D; Fantini J; Yahi N
    Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of glycolipids as potential HIV-1 fusion cofactors.
    Hammache D; Yahi N; Piéroni G; Ariasi F; Tamalet C; Fantini J
    Biochem Biophys Res Commun; 1998 May; 246(1):117-22. PubMed ID: 9600078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
    Fantini J; Hammache D; Delézay O; Yahi N; André-Barrès C; Rico-Lattes I; Lattes A
    J Biol Chem; 1997 Mar; 272(11):7245-52. PubMed ID: 9054420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
    Yahi N; Sabatier JM; Baghdiguian S; Gonzalez-Scarano F; Fantini J
    J Virol; 1995 Jan; 69(1):320-5. PubMed ID: 7983725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells.
    Fantini J; Hammache D; Delézay O; Piéroni G; Tamalet C; Yahi N
    Virology; 1998 Jul; 246(2):211-20. PubMed ID: 9657940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
    Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
    Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion.
    Fantini J; Hammache D; Piéroni G; Yahi N
    Glycoconj J; 2000; 17(3 -4):199-204. PubMed ID: 11201791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of human immunodeficiency virus type I (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop.
    Cook DG; Fantini J; Spitalnik SL; Gonzalez-Scarano F
    Virology; 1994 Jun; 201(2):206-14. PubMed ID: 8184533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane glycolipids and human immunodeficiency virus infection of primary macrophages.
    Seddiki N; Ben Younes-Chennoufi A; Benjouad A; Saffar L; Baumann N; Gluckman JC; Gattegno L
    AIDS Res Hum Retroviruses; 1996 May; 12(8):695-703. PubMed ID: 8744580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3).
    Hammache D; Yahi N; Maresca M; Piéroni G; Fantini J
    J Virol; 1999 Jun; 73(6):5244-8. PubMed ID: 10233996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric synthesis of water-soluble analogues of galactosylceramide, an HIV-1 receptor: new tools to study virus-glycolipid interactions.
    Villard R; Hammache D; Delapierre G; Fotiadu F; Buono G; Fantini J
    Chembiochem; 2002 Jun; 3(6):517-25. PubMed ID: 12325007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 activation of HIV fusion.
    Sattentau QJ
    Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
    Hill CM; Deng H; Unutmaz D; Kewalramani VN; Bastiani L; Gorny MK; Zolla-Pazner S; Littman DR
    J Virol; 1997 Sep; 71(9):6296-304. PubMed ID: 9261346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of human immunodeficiency virus type 1 gp120 binding to liposomes containing galactosylceramide.
    Long D; Berson JF; Cook DG; Doms RW
    J Virol; 1994 Sep; 68(9):5890-8. PubMed ID: 8057468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line.
    Harouse JM; Collman RG; González-Scarano F
    J Virol; 1995 Dec; 69(12):7383-90. PubMed ID: 7494242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
    Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
    J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275.
    Bhat S; Mettus RV; Reddy EP; Ugen KE; Srikanthan V; Williams WV; Weiner DB
    AIDS Res Hum Retroviruses; 1993 Feb; 9(2):175-81. PubMed ID: 8457384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.